Journal of Traditional Chinese Medicine ›› 2023, Vol. 43 ›› Issue (6): 1234-1242.DOI: 10.19852/j.cnki.jtcm.20230630.004
• Research Articles • Previous Articles Next Articles
Traditional Chinese Medicine syndrome analysis on oxaliplatin-induced peripheral neuropathy and clinical efficacy of Bushen Yiqi formula (补肾益气方): a prospective randomized controlled study
PAN Longci1, QI Chunhui2, SHEN Xubo3, HUANG Yixian1, YANG Xinrong2(
), SUN Xianjun4()
- 1 Department of Tradition Chinese Medicine, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai 201700, China
2 Department of Oncology, Shanghai Qingpu District Hospital of Traditional Chinese Medicine (the Clinical Base of The Institutes of Integrative Medicine, Fudan University), Shanghai 201799, China
3 Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
4 Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
-
Received:2022-09-12Accepted:2022-12-23Online:2023-10-25Published:2023-06-30 -
Contact:Prof. SUN Xianjun, Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China.brightsun@163.com; YANG Xinrong, Shanghai Qingpu District Hospital of Traditional Chinese Medicine, Shanghai 201799, China. yxr123111@163.com. Telephone: +86-21-52888331 -
Supported by:Innovative Research Team of High-Level Local University in Shanghai; the Discipline Construction and Talent Training Project in Qingpu District of Shanghai: the Fourth Round of Key Discipline Construction in Qingpu District(WZ2019-04);Fourth Round of Discipline Leader Training Plan in Qingpu District(WD2019-17/39 and WT-2019-02);Project of Qingpu District Science and Technology Committee: Study on the Mechanism of Icariin Regulating GR in the Treatment of OIPN(QKY2020-34)
Cite this article
PAN Longci, QI Chunhui, SHEN Xubo, HUANG Yixian, YANG Xinrong, SUN Xianjun. Traditional Chinese Medicine syndrome analysis on oxaliplatin-induced peripheral neuropathy and clinical efficacy of Bushen Yiqi formula (补肾益气方): a prospective randomized controlled study[J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1234-1242.
share this article
Table 1 Investigation of TCM syndrome elements and TCM syndromes in 89 patients with OIPN
| Syndrome element | Attribution of syndrome | Total number of cases (n) | Occurrence frequency (n) | Occurrence frequency (%) |
|---|---|---|---|---|
| Numbness or pain in the hands and feet | ABCDE | 89 | 89 | 100 |
| Paresthesia in the hands and feet | ABCDE | 89 | 89 | 100 |
| Fever in hands and feet | A | 89 | 4 | 4.49 |
| Cold in hands and feet | B | 89 | 17 | 19.1 |
| Numbness or pain in hands and feet, increased pain with cold, and decreased pain with heat | BC | 89 | 81 | 91.01 |
| Body lukewarm | C | 89 | 23 | 25.84 |
| Hand and foot pain and numbness, aggravated at night | E | 89 | 10 | 11.23 |
| Fever | A | 89 | 3 | 3.37 |
| Thirsty | A | 89 | 9 | 10.11 |
| Sweat | A | 89 | 6 | 6.74 |
| Yellow urine | A | 89 | 8 | 8.99 |
| Dry stool | A | 89 | 6 | 6.74 |
| Reluctance to drink | B | 89 | 16 | 17.98 |
| Aversion to wind and cold | B | 89 | 6 | 6.74 |
| Numbness and pain worsened on rainy days | B | 89 | 0 | 0 |
| Limb weakness | BD | 89 | 34 | 38.2 |
| Complexion white | C | 89 | 14 | 15.73 |
| Mental exhaustion | C | 89 | 28 | 31.46 |
| Soreness and weakness of waist and knees | CD | 89 | 39 | 43.82 |
| Dizzy | D | 89 | 7 | 7.87 |
| Dysphoria in the chest, palms, and soles | D | 89 | 3 | 3.37 |
| Hectic fever | D | 89 | 4 | 4.49 |
| Subcutaneous hard knots of hands and feet | E | 89 | 0 | 0 |
| Local skin color dull on hands and feet | E | 89 | 9 | 10.11 |
| Squamous and dry skin | E | 89 | 8 | 8.99 |
| Red tongue | AD | 89 | 28 | 31.46 |
| Pale red tongue | BC | 89 | 52 | 58.42 |
| Dark purple tongue | E | 89 | 9 | 10.11 |
| Yellow and greasy moss | A | 89 | 13 | 14.61 |
| White moss | BC | 89 | 60 | 67.42 |
| Less moss | D | 89 | 16 | 17.98 |
| Tongue with petechiae | E | 89 | 5 | 5.62 |
| Pulse slip or string slip | A | 89 | 8 | 8.99 |
| Tight pulse | B | 89 | 12 | 13.48 |
| Thin and weak pulse | C | 89 | 48 | 53.93 |
| Pulse sink fine string | D | 89 | 18 | 20.22 |
| Pulse sink thin and astringent | E | 89 | 11 | 12.35 |
Table 1 Investigation of TCM syndrome elements and TCM syndromes in 89 patients with OIPN
| Syndrome element | Attribution of syndrome | Total number of cases (n) | Occurrence frequency (n) | Occurrence frequency (%) |
|---|---|---|---|---|
| Numbness or pain in the hands and feet | ABCDE | 89 | 89 | 100 |
| Paresthesia in the hands and feet | ABCDE | 89 | 89 | 100 |
| Fever in hands and feet | A | 89 | 4 | 4.49 |
| Cold in hands and feet | B | 89 | 17 | 19.1 |
| Numbness or pain in hands and feet, increased pain with cold, and decreased pain with heat | BC | 89 | 81 | 91.01 |
| Body lukewarm | C | 89 | 23 | 25.84 |
| Hand and foot pain and numbness, aggravated at night | E | 89 | 10 | 11.23 |
| Fever | A | 89 | 3 | 3.37 |
| Thirsty | A | 89 | 9 | 10.11 |
| Sweat | A | 89 | 6 | 6.74 |
| Yellow urine | A | 89 | 8 | 8.99 |
| Dry stool | A | 89 | 6 | 6.74 |
| Reluctance to drink | B | 89 | 16 | 17.98 |
| Aversion to wind and cold | B | 89 | 6 | 6.74 |
| Numbness and pain worsened on rainy days | B | 89 | 0 | 0 |
| Limb weakness | BD | 89 | 34 | 38.2 |
| Complexion white | C | 89 | 14 | 15.73 |
| Mental exhaustion | C | 89 | 28 | 31.46 |
| Soreness and weakness of waist and knees | CD | 89 | 39 | 43.82 |
| Dizzy | D | 89 | 7 | 7.87 |
| Dysphoria in the chest, palms, and soles | D | 89 | 3 | 3.37 |
| Hectic fever | D | 89 | 4 | 4.49 |
| Subcutaneous hard knots of hands and feet | E | 89 | 0 | 0 |
| Local skin color dull on hands and feet | E | 89 | 9 | 10.11 |
| Squamous and dry skin | E | 89 | 8 | 8.99 |
| Red tongue | AD | 89 | 28 | 31.46 |
| Pale red tongue | BC | 89 | 52 | 58.42 |
| Dark purple tongue | E | 89 | 9 | 10.11 |
| Yellow and greasy moss | A | 89 | 13 | 14.61 |
| White moss | BC | 89 | 60 | 67.42 |
| Less moss | D | 89 | 16 | 17.98 |
| Tongue with petechiae | E | 89 | 5 | 5.62 |
| Pulse slip or string slip | A | 89 | 8 | 8.99 |
| Tight pulse | B | 89 | 12 | 13.48 |
| Thin and weak pulse | C | 89 | 48 | 53.93 |
| Pulse sink fine string | D | 89 | 18 | 20.22 |
| Pulse sink thin and astringent | E | 89 | 11 | 12.35 |
Figure 1 Flow diagram of this trial BSYQF: Bushen Yiqi formula.
Figure 1 Flow diagram of this trial BSYQF: Bushen Yiqi formula.
Table 2 Comparison of baseline data between the two groups of patients ( x -± s)
| Group | Sex (n) | Age (years) | Single dose of oxaliplatin (mg) | Cumulative dose of oxaliplatin (mg) | |
|---|---|---|---|---|---|
| Male | Female | ||||
| Control | 23 | 8 | 64±9 | 190±45 | 801±113 |
| Treatment | 21 | 10 | 63±8 | 197±46 | 817±116 |
Table 2 Comparison of baseline data between the two groups of patients ( x -± s)
| Group | Sex (n) | Age (years) | Single dose of oxaliplatin (mg) | Cumulative dose of oxaliplatin (mg) | |
|---|---|---|---|---|---|
| Male | Female | ||||
| Control | 23 | 8 | 64±9 | 190±45 | 801±113 |
| Treatment | 21 | 10 | 63±8 | 197±46 | 817±116 |
Table 3 Changes in the Levi sensory neurotoxicity score before and after treatment in 62 patients in 2 groups (n)
| Group | Time | Total cases | Level 0 | Level 1 | Level 2 | Level 3 | Level 4 | Markedly effective cases | Effective cases |
|---|---|---|---|---|---|---|---|---|---|
| Treatment | Pretreatment | 31 | 0 | 9 | 9 | 10 | 3 | 11 | 24a |
| Post-treatment | 31 | 8 | 13 | 4 | 5 | 1 | |||
| Control | Pretreatment | 31 | 0 | 11 | 10 | 10 | 0 | 7 | 14 |
| Post-treatment | 31 | 0 | 9 | 9 | 10 | 3 |
Table 3 Changes in the Levi sensory neurotoxicity score before and after treatment in 62 patients in 2 groups (n)
| Group | Time | Total cases | Level 0 | Level 1 | Level 2 | Level 3 | Level 4 | Markedly effective cases | Effective cases |
|---|---|---|---|---|---|---|---|---|---|
| Treatment | Pretreatment | 31 | 0 | 9 | 9 | 10 | 3 | 11 | 24a |
| Post-treatment | 31 | 8 | 13 | 4 | 5 | 1 | |||
| Control | Pretreatment | 31 | 0 | 11 | 10 | 10 | 0 | 7 | 14 |
| Post-treatment | 31 | 0 | 9 | 9 | 10 | 3 |
Table 4 Changes in Levi sensory neurotoxicity scores before and after treatment in 18 patients with cold-dampness obstruction symptoms (n)
| Group | Time | Total cases | Level 0 | Level 1 | Level 2 | Level 3 | Level 4 | Markedly effective cases | Effective cases |
|---|---|---|---|---|---|---|---|---|---|
| Treatment | Pretreatment | 9 | 2 | 3 | 3 | 1 | 3 | 6 | |
| Post-treatment | 9 | 2 | 4 | 1 | 2 | 0 | |||
| Control | Pretreatment | 9 | 3 | 3 | 3 | 0 | 2 | 5 | |
| Post-treatment | 9 | 2 | 3 | 2 | 2 | 0 |
Table 4 Changes in Levi sensory neurotoxicity scores before and after treatment in 18 patients with cold-dampness obstruction symptoms (n)
| Group | Time | Total cases | Level 0 | Level 1 | Level 2 | Level 3 | Level 4 | Markedly effective cases | Effective cases |
|---|---|---|---|---|---|---|---|---|---|
| Treatment | Pretreatment | 9 | 2 | 3 | 3 | 1 | 3 | 6 | |
| Post-treatment | 9 | 2 | 4 | 1 | 2 | 0 | |||
| Control | Pretreatment | 9 | 3 | 3 | 3 | 0 | 2 | 5 | |
| Post-treatment | 9 | 2 | 3 | 2 | 2 | 0 |
Table 5 Changes in the Levi sensory neurotoxicity score before and after treatment in 44 patients with kidney-Qi deficiency and cold symptom (n)
| Group | Time | Total cases | Level 0 | Level 1 | Level 2 | Level 3 | Level 4 | Markedly effective case | Effective case |
|---|---|---|---|---|---|---|---|---|---|
| Treatment | Pretreatment | 22 | 7 | 6 | 7 | 2 | 8 | 18a | |
| Post-treatment | 22 | 6 | 9 | 3 | 3 | 1 | |||
| Control | Pretreatment | 22 | 8 | 7 | 7 | 0 | 5 | 9 | |
| Post-treatment | 22 | 4 | 9 | 4 | 5 | 0 |
Table 5 Changes in the Levi sensory neurotoxicity score before and after treatment in 44 patients with kidney-Qi deficiency and cold symptom (n)
| Group | Time | Total cases | Level 0 | Level 1 | Level 2 | Level 3 | Level 4 | Markedly effective case | Effective case |
|---|---|---|---|---|---|---|---|---|---|
| Treatment | Pretreatment | 22 | 7 | 6 | 7 | 2 | 8 | 18a | |
| Post-treatment | 22 | 6 | 9 | 3 | 3 | 1 | |||
| Control | Pretreatment | 22 | 8 | 7 | 7 | 0 | 5 | 9 | |
| Post-treatment | 22 | 4 | 9 | 4 | 5 | 0 |
Table 6 Neuroelectrophysiological changes before and after treatment in 62 patients
| NCV | Measuring limbs | Control group | Treatment group | |||
|---|---|---|---|---|---|---|
| Pretreatment (n = 31) | Post-treatment (n = 31) | Pretreatment (n = 31) | Post-treatment (n = 31) | |||
| Ulnar nerve (M, m/s) | Left | 49.1±3.6 | 50.3±3.1 | 48.7±3.2 | 54.5±3.5b | |
| Right | 47.6±4.2 | 48.3±3.3 | 46.2±3.9 | 53.6±4.6b | ||
| Radial nerve (M, m/s) | Left | 48.2±5.1 | 48.9±4.7 | 47.2±8.3 | 49.5±7.7 | |
| Right | 47.9±3.2 | 48.5±8.5 | 46.8±4.9 | 48.1±3.9 | ||
| Median nerve (M, m/s) | Left | 56.8±4.5 | 55.9±8.9 | 55.7±9.2 | 54.9±8.5 | |
| Eight | 56.1±5.1 | 57.0±7.4 | 55.6±3.5 | 55.1±5.6 | ||
| Peroneal nerve (M, m/s) | Left | 47.6±4.2 | 48.1±4.3 | 47.1±7.2 | 47.9±7.6 | |
| Right | 46.9±3.7 | 47.5±6.7 | 46.3±5.1 | 46.8±4.1 | ||
| Ulnar nerve (S, m/s) | Left | 48.7±8.3 | 52.7±6.2a | 48.1±5.9 | 55.5±3.5b | |
| Right | 47.6±3.9 | 51.3±3.3a | 46.8±5.6 | 54.6±4.6b | ||
| Radial nerve (S, m/s) | Left | 58.5±7.1 | 58.9±7.8 | 57.1±8.5 | 58.7±8.4 | |
| Right | 57.1±6.2 | 58.5±7.2 | 56.4±7.5 | 57.1±6.9 | ||
| Median nerve (S, m/s) | Left | 57.1±4.9 | 57.9±4.1 | 56.7±5.1 | 57.9±4.6 | |
| Right | 56.7±5.2 | 57.0±4.2 | 55.9±4.5 | 56.3±4.6 | ||
| Peroneal nerve (S, m/s) | Left | 41.7±6.3 | 42.5±5.1 | 40.1±7.8 | 45.8±7.5b | |
| Right | 42.3±6.7 | 43.8±8.8 | 41.6±5.1 | 46.9±7.1b | ||
Table 6 Neuroelectrophysiological changes before and after treatment in 62 patients
| NCV | Measuring limbs | Control group | Treatment group | |||
|---|---|---|---|---|---|---|
| Pretreatment (n = 31) | Post-treatment (n = 31) | Pretreatment (n = 31) | Post-treatment (n = 31) | |||
| Ulnar nerve (M, m/s) | Left | 49.1±3.6 | 50.3±3.1 | 48.7±3.2 | 54.5±3.5b | |
| Right | 47.6±4.2 | 48.3±3.3 | 46.2±3.9 | 53.6±4.6b | ||
| Radial nerve (M, m/s) | Left | 48.2±5.1 | 48.9±4.7 | 47.2±8.3 | 49.5±7.7 | |
| Right | 47.9±3.2 | 48.5±8.5 | 46.8±4.9 | 48.1±3.9 | ||
| Median nerve (M, m/s) | Left | 56.8±4.5 | 55.9±8.9 | 55.7±9.2 | 54.9±8.5 | |
| Eight | 56.1±5.1 | 57.0±7.4 | 55.6±3.5 | 55.1±5.6 | ||
| Peroneal nerve (M, m/s) | Left | 47.6±4.2 | 48.1±4.3 | 47.1±7.2 | 47.9±7.6 | |
| Right | 46.9±3.7 | 47.5±6.7 | 46.3±5.1 | 46.8±4.1 | ||
| Ulnar nerve (S, m/s) | Left | 48.7±8.3 | 52.7±6.2a | 48.1±5.9 | 55.5±3.5b | |
| Right | 47.6±3.9 | 51.3±3.3a | 46.8±5.6 | 54.6±4.6b | ||
| Radial nerve (S, m/s) | Left | 58.5±7.1 | 58.9±7.8 | 57.1±8.5 | 58.7±8.4 | |
| Right | 57.1±6.2 | 58.5±7.2 | 56.4±7.5 | 57.1±6.9 | ||
| Median nerve (S, m/s) | Left | 57.1±4.9 | 57.9±4.1 | 56.7±5.1 | 57.9±4.6 | |
| Right | 56.7±5.2 | 57.0±4.2 | 55.9±4.5 | 56.3±4.6 | ||
| Peroneal nerve (S, m/s) | Left | 41.7±6.3 | 42.5±5.1 | 40.1±7.8 | 45.8±7.5b | |
| Right | 42.3±6.7 | 43.8±8.8 | 41.6±5.1 | 46.9±7.1b | ||
Table 7 Hematological indicators in 62 patients( x - ± s)
| Item | Control group | Treatment group | ||||
|---|---|---|---|---|---|---|
| Pretreatment (n = 31) | Post-treatment (n = 31) | Pretreatment (n = 31) | Post-treatment (n = 31) | |||
| Leukocyte (×109/L) | 5.8±2.0 | 5.6±2.1 | 5.7±2.7 | 6.1±2.9 | ||
| Hemoglobin (g/L) | 98.4±25.7 | 102.1±32.4 | 89.5±28.3 | 97.4±37.5 | ||
| Platelets (×109/L) | 198.6±72.3 | 209.1±75.6 | 205.2±79.1 | 219.1±76.4 | ||
| AST (U/L) | 29.5±14.2 | 28.2±17.6 | 31.2±17.1 | 30.8±18.7 | ||
| ALT (U/L) | 28.2±18.3 | 25.8±16.7 | 29.4±15.8 | 32.5±19.8 | ||
| Urea (mmol/L) | 4.6±1.1 | 4.6±1.8 | 5.0±1.0 | 4.8±1.6 | ||
| Creatinine (μmol/L) | 67.3±24.1 | 64.9±19.1 | 61.7±15.2 | 58.3±14.9 | ||
Table 7 Hematological indicators in 62 patients( x - ± s)
| Item | Control group | Treatment group | ||||
|---|---|---|---|---|---|---|
| Pretreatment (n = 31) | Post-treatment (n = 31) | Pretreatment (n = 31) | Post-treatment (n = 31) | |||
| Leukocyte (×109/L) | 5.8±2.0 | 5.6±2.1 | 5.7±2.7 | 6.1±2.9 | ||
| Hemoglobin (g/L) | 98.4±25.7 | 102.1±32.4 | 89.5±28.3 | 97.4±37.5 | ||
| Platelets (×109/L) | 198.6±72.3 | 209.1±75.6 | 205.2±79.1 | 219.1±76.4 | ||
| AST (U/L) | 29.5±14.2 | 28.2±17.6 | 31.2±17.1 | 30.8±18.7 | ||
| ALT (U/L) | 28.2±18.3 | 25.8±16.7 | 29.4±15.8 | 32.5±19.8 | ||
| Urea (mmol/L) | 4.6±1.1 | 4.6±1.8 | 5.0±1.0 | 4.8±1.6 | ||
| Creatinine (μmol/L) | 67.3±24.1 | 64.9±19.1 | 61.7±15.2 | 58.3±14.9 | ||
| 1. |
Ter Veer E, van Oijen MGH, van Laarhoven HWM. S-1 with leucovorin and oxaliplatin for advanced gastric cancer. Lancet Oncol 2016; 17: e41.
DOI PMID |
| 2. |
Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: the present and the future. World J Hepatol 2017; 9: 907-20.
DOI PMID |
| 3. |
Neuzillet C, Gaujoux S, Williet N, et al. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018; 50: 1257-71.
DOI URL |
| 4. |
Conteduca V, Gurioli G, Rossi L, et al. Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. BMC Cancer 2018; 18: 1267.
DOI PMID |
| 5. | André T, Vernerey D, Mineur L, et al. Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage Ⅲ colon cancer: disease-free survival results from a randomized, open-label, international duration evaluation of adjuvant (IDEA) france, phase Ⅲ trial. J Clin Oncol 2018; 36: 1469-77. |
| 6. | Pachman DR, Qin R, Seisler DK, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase Ⅲ trial N08CB (Alliance). J Clin Oncol 2015; 33: 3416-22. |
| 7. | Drott J, Fomichov V, Starkhammar H, Börjeson S, Kjellgren K, Berterö C. Oxaliplatin-induced neurotoxic side effects and their impact on daily activities: a longitudinal study among patients with colorectal cancer. Cancer Nurs 2019; 42: E40-8. |
| 8. | Soveri LM, Lamminmäki A, Hänninen UA, Karhunen M, Bono P, Osterlund P. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. Acta Oncol 2019; 58: 398-406. |
| 9. | The Ministry of Health of the People's Republic of China. Guiding Principles for Clinical research of new Chinese medicine (Volume 1). Beijing: the Ministry of Health of the People's Republic of China, 1992: 210-5. |
| 10. | Zheng XY. Guiding Principles for clinical research of new Chinese medicine. Beijing: the Medicine Science and Technology Press of China, 2002: 115-9. |
| 11. | Deng TT, Deng ZY, Luo YK. TCM syndrome specification. Guangzhou: Guangzhou Science and Technology Press, 1990: 55-9, 86-9, 168-70. |
| 12. |
Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J Am Acad Dermatol 2012; 67: 1025-39.
DOI PMID |
| 13. |
Schmitt LI, Leo M, Kleinschnitz C, Hagenacker T. Oxaliplatin modulates the characteristics of voltage-gated calcium channels and action potentials in small dorsal root ganglion neurons of rats. Mol Neurobiol 2018; 55: 8842-55.
DOI |
| 14. |
Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci USA 2012; 109: 6704-9.
DOI PMID |
| 15. |
Li L, Shao J, Wang J, et al. MiR-30b-5p attenuates oxaliplatin-induced peripheral neuropathic pain through the voltage-gated sodium channel Nav1.6 in rats. Neuropharmacology 2019; 153: 111-20.
DOI URL |
| 16. |
Riva B, Dionisi M, Potenzieri A, et al. Oxaliplatin induces pH acidification in dorsal root ganglia neurons. Sci Rep 2018; 8: 15084.
DOI PMID |
| 17. | Makker PG, Duffy SS, Lees JG, et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. PLoS One 2017; 12: e0170814. |
| 18. |
Livni L, Lees JG, Barkl-Luke ME, Goldstein D, Moalem-Taylor G. Dorsal root ganglion explants derived from chemotherapy-treated mice have reduced neurite outgrowth in culture. Neurosci Lett 2019; 694: 14-9.
DOI PMID |
| 19. |
Hershman DL, Lacchetti C, Dworkin RH, et al. American Society of Clinical O Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014; 32: 1941-67.
DOI PMID |
| 20. | Sun XJ, Lü YB, Wang JJ, et al. Differential protein expression profiling by iTRAQ‐2D‐LC‐MS/MS of rats treated with oxaliplatin. J Cell Biochem 2019;120: 18128-41. |
| 21. |
Kong LW, Wu JF, Lin Y, et al. Bushen Yiqi granule inhibits atopic dermatitis via improving central and skin hypothalamic-pituitary-adrenal axis function. PloS One 2015; 10: e0116427.
DOI URL |
| 22. |
Cui J, Xu F, Tang Z, et al. Bu-Shen-Yi-Qi formula ameliorates airway remodeling in murine chronic asthma by modulating airway inflammation and oxidative stress in the lung. Biomed Pharmacother 2019; 112: 108694.
DOI URL |
| 23. |
Wei Y, Luo QL, Sun J, Chen MX, Liu F, Dong JC. Bu-Shen-Yi-Qi formulae suppress chronic airway inflammation and regulate Th17/Treg imbalance in the murine ovalbumin asthma model. J Ethnopharmacol 2015; 164: 368-77.
DOI PMID |
| 24. | Sun XJ, Deng XH, Cai WJ, et al. Icariin inhibits LPS-induced cell inflammatory response by promoting GRα nuclear translocation and upregulating GRα expression. Life Sciences 2018; 195: 33-43. |
| 25. |
Sun XJ, Cheng HQ, Liu BJ, et al. Icariin reduces LPS induced acute lung injury in mice undergoing bilateral adrenalectomy by regulating GRα. Eur J Pharmacol 2020; 876: 173032.
DOI URL |
| 26. | Tian DH. Huang Di Nei Jing Su Wen. Beijing: People's Medical Publishing House, 2005: 181. |
| 27. | Wang J. Principles of medicine. Beijing: China Press of Traditional Chinese Medicine, 2009: 235. |
| No related articles found! |
| Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Full text 177
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
Abstract 136
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
